ResMed (RMD) PT Raised to $280 at KeyBanc after a 'Positive 2Q25 Driven by Devices'
Tweet Send to a Friend
KeyBanc analyst Brett Fishbin raised the price target on ResMed (NYSE: RMD) to $280.00 (from $266.00) while maintaining an Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
